Lipidil

Fenofibrate, the active ingredient in Lipidil, is a fibric acid derivative presented as an oral tablet for oral use. It treats hypertriglyceridemia, mixed dyslipidemia and hypercholesterolemia in adult patients.

GNH USA supplies Lipidil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Fenofibrate acts on lipid metabolism pathways to modify abnormal blood lipid levels. - Hypertriglyceridemia: lowers elevated triglyceride concentrations. - Mixed dyslipidemia: improves the overall lipid profile by reducing triglycerides and modestly increasing HDL‑cholesterol. - Hypercholesterolemia: contributes to a reduction in LDL‑cholesterol when used as part of combination therapy.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal pain, or dyspepsia. - Headache: mild to moderate intensity. - Myalgia: muscle aches without weakness. - Elevated liver enzymes: transient increases in ALT/AST. - Rash: mild skin irritation or pruritus.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with potential renal impairment. - Acute liver injury: marked elevation of hepatic enzymes or jaundice. - Severe allergic reactions: anaphylaxis, angioedema, or Stevens‑Johnson syndrome. - Pancreatitis: acute inflammation of the pancreas. - Hepatotoxicity: liver failure in predisposed individuals. - Blood dyscrasias: rare cases of neutropenia or thrombocytopenia.

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor relevant laboratory parameters. - Liver function monitoring: obtain baseline ALT/AST and repeat periodically. - Renal function assessment: evaluate creatinine clearance, especially in elderly patients. - Muscle symptom vigilance: educate patients to report unexplained muscle pain or weakness. - Concomitant statin use: review dose and potential for myopathy. - Severe hepatic impairment: avoid use in patients with established liver disease. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Fenofibrate may interact with several drug classes, requiring dose adjustments or monitoring.

Major Interactions (Avoid): - Gemfibrozil: markedly increases risk of rhabdomyolysis. - Cyclosporine: elevates fenofibrate plasma concentrations. - Anticoagulants (e.g., warfarin): may enhance anticoagulant effect and bleeding risk.

Moderate Interactions (Monitor Closely): - Statins (especially high‑dose simvastatin or atorvastatin): increased myopathy risk. - Bile‑acid sequestrants (e.g., cholestyramine): may reduce fenofibrate absorption. - Oral contraceptives: potential alteration of lipid parameters; monitor efficacy.